CorMedix shareholders elect 7 directors, approve executive pay, ratify Marcum as auditor

Proposal No. 2 – Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers for 2022 . Proposal No. 2 was to approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers for 2022, as disclosed in the Proxy Statement. The proposal was approved. The results of the vote taken were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 12,781,884 4,234,480 123,537 21,612,075

The following individuals, each of whom was named as a nominee in the Proxy Statement, were elected by the Company’s stockholders by a plurality of votes cast to serve on the Company’s board of directors until the Company’s 2024 annual meeting of stockholders. Information on the vote relating to each director standing for election is set forth below: Nominee FOR WITHHELD BROKER NON-VOTES Janet Dillione 10,598,504 6,541,397 21,612,075 Gregory Duncan 15,929,357 1,210,544 21,612,075 Alan W. Dunton 15,731,113 1,408,788 21,612,075 Myron Kaplan 11,246,141 5,893,760 21,612,075 Steven Lefkowitz 16,007,358 1,132,543 21,612,075 Joseph Todisco 12,774,071 4,365,830 21,612,075 Robert Stewart 16,175,492 964,409 21,612,075

Proposal No. 3 - Ratification of Appointment of Independent Registered Public Accounting Firm . Proposal No. 3 was to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved. The results of the vote taken were as follows: FOR AGAINST ABSTAIN 37,796,427 700,384 255,165